mRNA levels of liver steatosis markers like SREBP1c (stimulate liver lipid synthesis), monocytes chemoattractant protein-1 (MCP1, a proinflammatory cytokine) and APOB100 (apolipoprotein of chylomicrons and low-density lipoproteins (LDL)) were reduced in CNX-012-570 treatment animals as compared to HFD control animals (Figure 4F). This evidence concerns the gene CCL2 and fatty liver disease.